UPDATE 1-Savient to offer 4 mln shares

* Says to use proceeds to seek FDA nod for gout drug

* Shares down 6 percent

Oct 7 (Reuters) - Savient Pharmaceuticals Inc (SVNT.O) said it intends to offer four million common shares and use the net proceeds toward resubmission of marketing application for its experimental gout drug, Krystexxa, and other related activities.

The company also plans to grant the underwriters an over-allotment option to purchase up to 600,000 additional shares.

J.P. Morgan Securities Inc is acting as sole book-running manager of the proposed offering.

Last month, Savient had said the U.S. Food and Drug Administration do not expect additional trials for Krystexxa, which was denied approval in July. [ID:nBNG14500]

Shares of the company fell to $14.15 in after market trade. They closed at $15.07 Wednesday on Nasdaq.

(Reporting by Shailesh Kuber in Bangalore; Editing by Anil D'Silva)